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Summary 
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, 
VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), 
assessed the intake of niacin in the Norwegian population. NFSA has also requested that 
VKM conduct scenario calculations to illustrate the consequences of establishing separate 
maximum limits for nicotinic acid (1, 4, 8 or 10 mg/day) and nicotinamide (100, 500, 700 or 
900 mg/day) in food supplements, by assessing these scenarios against existing tolerable 
upper intake levels (ULs). The current maximum limit for niacin added to food supplements 
is 32 mg/day, including nicotinic acid, nicotinamide and inositol hexanicotinate. 
The term niacin (vitamin B3) comprises the two main water-soluble forms nicotinic acid and 
nicotinamide (niacinamide). The human body can get niacin from the diet or synthesise it 
from the essential amino acid tryptophan. Dietary intakes are expressed as milligram niacin 
equivalents (NEs), which correspond to 1 mg of pure niacin or 60 mg of tryptophan.  
In the body, niacin primarily functions as a component of the coenzymes NAD (nicotinamide 
adenine dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate) which are 
present in all cells. These coenzymes play essential roles for the functioning of a wide range 
of enzymes involved in the metabolism of carbohydrates, amino acids and fat. In addition to 
its function in coenzymes, niacin is involved in DNA repair and gene stability. Niacin has a 
half-life of 20-40 minutes in the human body. 
Late symptoms of severe niacin deficiency (pellagra) include fatigue, headache, apathy, 
depression, memory loss, dementia, pigmented skin rash after sun exposure, bright red 
tongue, vomiting, diarrhoea, and constipation. 
Flushing (burning and itching of the face, arms and chest) and stomach irritation are the 
main side effects of moderately high supplemental intake of nicotinic acid (>35 mg/day). 
Long-term use of high doses (≥3000 mg/day) of nicotinic acid as a cholesterol-lowering drug 
can also be toxic to the liver. Nicotinamide, however, does not have these effects. In 
general, the risk of nicotinamide toxicity appears to be quite low. 
VKM proposes to adopt the ULs of nicotinic acid and nicotinamide set by the Scientific 
Committee for Food Safety (SCF) in 2002, which are based on one human dose-response 
study (nicotinic acid) and several human dose-response studies (nicotinamide), respectively. 
Hence, the UL for supplemental nicotinic acid is suggested to 10 mg/day for adults and the 
UL for supplemental nicotinamide to 900 mg/day for adults. The ULs for children and 
adolescents have been derived on the basis of their body weights. 
The ULs set for nicotinic acid and nicotinamide concern only intake from supplements since 
intake of nicotinic acid and nicotinamide from regular foods is considered to be without risk 
of negative health effects. Therefore, VKM has not conducted or evaluated scenarios with 
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intake from both diet and the separated new maximum limits for nicotinic acid and 
nicotinamide in food supplements suggested by NFSA.  
Dietary calculations, however, have been performed for niacin intakes (includes both 
nicotinic acid and nicotinamide) in various percentiles (P5, P25, mean, P50, P75 and P95) in 
children (2-, 4- and 9-year-olds), adolescents (13-year-olds) and adults as background 
information. 
Mean and median intakes of niacin from the diet alone are above or at the recommended 
intakes for all age groups.  
Because UL for supplemental nicotinic acid is 10 mg/day for adults, none of the suggested 
maximum limits in food supplements (1, 4, 8, or 10 mg/day) will lead to exceedance of this 
UL in adults. In 13-year-olds and 9-year-olds, supplements with 8 mg nicotinic acid per day 
will lead to exceedance of UL, and in 4-year-olds and 2-year-olds supplementation of 4 mg 
nicotinic acid per day will lead to exceedance of the UL for nicotinic acid. 
Because UL for supplemental nicotinamide is 900 mg/day for adults, none of the suggested 
maximum limits in food supplements (100, 500, 700 or 900 mg/day) will lead to exceedance 
of UL in adults. In 13-year-olds, supplements with 700 mg nicotinamide per day will lead to 
exceedance of UL. In 9-year-olds, 4-year-olds and 2-year-olds, supplementation of 500 mg 
nicotinamide per day will lead to exceedance of the UL for nicotinic acid. 
Key words: VKM, risk assessment, Norwegian Scientific Committee for Food Safety, niacin, 
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Sammendrag på norsk 
På oppdrag fra Mattilsynet har Vitenskapskomiteen for mattrygghet vurdert inntaket av 
niacin i den norske befolkningen. Mattilsynet har også bedt VKM om å gjøre 
scenarioberegninger for å illustrere konsekvensene av å etablere separate 
maksimumsgrensene i kosttilskudd for nikotinsyre (på 1, 4, 8 eller 10 mg/dag) og 
nikotinamid (på 100, 500, 700 eller 900 mg /dag), og vurdere disse scenariene mot 
eksisterende tolerable øvre inntaksnivåer (UL). Dagens maksimumsgrense i kosttilskudd er 
kun satt for niacin, og er 32 mg/dag og inkluderer nikotinsyre, nikotinamid og 
inositolheksanikotinat (inositolheksaniacinat). 
Niacin (vitamin B3) er vannløselig og finnes i to hovedformer; nikotinsyre og nikotinamid 
(niacinamid). Vi kan få i oss niacin fra kosten eller ved å syntetisere det fra den essensielle 
aminosyren tryptofan. Inntak av niacin fra kosten uttrykkes som niacinekvivalenter (NE), og 
1 NE tilsvarer 1 mg niacin eller 60 mg tryptofan. 
I kroppen inngår niacin i koenzymene NAD (nikotinamid dinukleotid) og NADP (nikotinamid 
dinukleotid fosfat), som finnes i alle celler og spiller avgjørende roller for funksjonen til en 
rekke enzymer som er involvert i metabolismen av karbohydrat, aminosyrer og fett. I tillegg 
til å fungere som koenzym, er niacin også involvert i reparasjon av DNA og bevaring av 
genetisk stabilitet. Niacin har en halveringstid på 20-40 minutter i kroppen. 
Alvorlig niacin-mangel (pellagra) gir symptomer som tretthet, hodepine, apati, depresjon, 
hukommelsestap, demens, økt hudpigmentering etter eksponering for sollys, lys rød tunge, 
oppkast, diaré og forstoppelse. 
Et moderat høyt inntak av nikotinsyre (>35 mg/dag) fra kosttilskudd kan gi bivirkninger som 
rødming (brennende kløe i ansikt, på armer og bryst), og irritabel mage. Inntak av veldig 
høye doser nikotinsyre (≥3000 mg/dag) over lang tid, f.eks. ved bruk av kolesterolsenkende 
medikamenter, kan i verste fall medføre leversvikt. Inntak av nikotinamid, har ikke vist slike 
effekter. Generelt har nikotinamid vist lav toksisitet. 
VKM foreslår at de øvre tolerable inntaksnivåene for nikotinsyre og nikotinamid som EUs 
tidligere vitenskapskomité for mat (Scientific Committee for Food) fastsatte i 2002, benyttes 
for den norske befolkningen. Disse inntaksnivåene er basert på humanstudier hvor det er 
gjort dose-responsforsøk, hvorav én studie er gjort på nikotinsyre og flere på nikotinamid.  
På bakgrunn av disse studiene foreslår VKM at det øvre tolerable inntaksnivå for tilskudd av 
nikotinsyre er 10 mg/dag og for nikotinamid 900 mg/dag. Tolerable øvre inntaksnivå for barn 
og unge ble ekstrapolert basert på kroppsvekt. 
Ettersom inntak av nikotinsyre og nikotinamid fra kosten anses å være uten risiko for 
negative helseeffekter, gjelder disse tolerable øvre inntaksnivåene kun for inntak av 
nikotinsyre og nikotinamid fra tilskudd. VKM har derfor ikke gjort scenarioberegninger som 
inkluderer inntak av nikotinsyre og nikotinamid fra mat. 
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VKM har imidlertid gjort inntaksberegninger av nikotinsyre og nikotinamid for ulike 
persentiler (P) for inntak (P5, P25, P50, P75 og P95), samt gjennomsnittlig inntak hos barn 
(2-, 4- og 9-åringer), ungdom (13-åringer) og voksne menn og kvinner som 
bakgrunnsinformasjon. 
Gjennomsnittet og medianen av inntak av niacin fra kosten (uten kosttilskudd) overstiger 
eller samsvarer med anbefalt inntak i alle aldersgrupper.  
Ettersom tolerabelt øvre inntaksnivå for nikotinsyre i tilskuddsform for voksne er 10 mg/dag, 
vil ingen av de foreslåtte maksimumsgrensene i kosttilskudd (1, 4, 8 eller 10 mg/dag) føre til 
overskridelser at øvre inntaksnivået hos voksne. For 9- og 13-åringer vil kosttilskudd med 
8 mg nikotinsyre/dag, og for 4- og 2-åringer vil kosttilskudd med 4 mg nikotinsyre/dag føre 
til overskridelse av det øvre inntaksnivået. 
Ettersom tolerable øvre inntaksnivå for nikotinamid i tilskuddsform for voksne er 900 
mg/dag, vil ingen av de foreslåtte maksimumsgrensene i kosttilskudd (100, 500, 700 eller 
900 mg/dag) føre til overskridelser at det øvre inntaksnivået hos voksne. For 13-åringer vil 
kosttilskudd med 700 mg nikotinamid/dag, og for 2-, 4- og 9-åringer vil kosttilskudd med 
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Abbreviations and/or glossary 
Abbreviations 
AI – adequate intake 
AR  – average requirement 
bw  – body weight 
CI  – confidence interval 
DNA  – deoxyribonucleic acid 
DRI  – dietary reference intake 
DRV  – dietary reference value 
EAR  – estimated average requirement (IOM).  
EFSA  – European Food Safety Authority 
EVM  – Expert group on vitamins and minerals of the Food Standard Agency, UK 
IOM  – Institute of Medicine, USA 
IU  – international unit 
LOAEL  – lowest observed adverse effect level 
NAD  – nicotinamide adenine dinucleotide 
NADH  – reduced nicotinamide adenine dinucleotide 
NADP  – nicotinamide adenine dinucleotide phosphate 
NADPH – reduced nicotinamide adenine dinucleotide phosphate 
NE  – niacin eqivalent 
NFSA  – Norwegian Food Safety Authority [Norw.: Mattilsynet] 
NNR  – Nordic Nutrition Recommendations 
NOAEL  – no observed adverse effect level 
MJ  – mega joule 
PRI  – population reference intakes 
RDA  – recommended dietary allowances 
RI  – recommended intake 
SCF  – Scientific Committee for Food 
SUL  – safe upper intake level 
UF  – uncertainty factor 
UL  – tolerable upper intake level 
VKM  – Norwegian Scientific Committee for Food Safety [Norw.: Vitenskapskomiteen 
for Mattrygghet] 
Glossary 
P5, P25, P50, P75 or P95-exposure is the calculated exposure at the 5, 25, 50, 75 or 95-
percentile. 
Percentile is a term for visualising the low, medium and high occurrences of a 
measurement by splitting the whole distribution into one hundred equal parts. A percentile is 
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a statistical measure indicating the value below which a given percentage of the observations 
fall. E.g. the 95-percentile is the value (or score) below which 95 percent of the observations 
are found. 
EFSA - Dietary Reference Values (DRVs) (EFSA, 2010)  
Average Requirement (AR) is the level of intake of a defined group of individuals 
estimated to satisfy the physiological requirement of metabolic demand, as defined by a 
specific criterion for adequacy for the nutrient, in half of the heathy individuals in a life stage 
or sex group, on the assumption that the supply of other nutrients and energy is adequate.   
If an AR cannot be determined than an Adequate Intake is used.   
Adequate Intake (AI) is defined as the average (median) daily level of intake based on 
observed, or experimentally determined approximations or estimates of a nutrient intake, by 
a group (or groups) of apparently healthy people, and therefore assumed to be adequate. 
The practical implication of an AI is similar to that of a population reference intake, i.e. to 
describe the level of intake that is considered adequate for health reasons. The 
terminological distinction relates to the different ways in which these values are derived and 
to the resultant difference in the “firmness” of the value.  
Population Reference Intake (PRI) is derived from AR of a defined group of individuals 
in an attempt to take into account the variation of requirements between individuals.  
 
 
Figure 1: Population reference intake (PRI and average requirements (AR), if the requirement has a 
normal distribution and the inter-individual variation is known (EFSA, 2010). 
Lower Threshold Intake (LTI) is the lowest estimate of requirement from the normal 
distribution curve, and is generally calculated on the basis of the AR minus twice its SD. This 
will meet the requirement of only 2.5% of the individuals in the population.  
Tolerable Upper intake Level (UL) is the maximum level of total chronic daily intake of a 
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Figure 2: Relationship between individual intake and risk of adverse effects due to insufficient or 
excessive intake. 
IOM - Dietary Reference Intakes (DRIs) (IOM, 2000)  
Estimated Average Requirement (EAR) is a nutrient intake value that is estimated to 
meet the requirement of half the healthy individuals in a life stage and gender group.  
Recommended Dietary Allowances (RDA) is the dietary intake level that is sufficient to 
meet the nutrient requirement of nearly all (97 to 98 percent) healthy individuals in a 
particular life stage and gender group. RDA = EAR + 2 SDEAR or if insufficient data to 
calculate SD a factor of 1.2 is used to calculate RDA; RDA = 1.2*EAR 
Adequate Intake (AI) is the recommended intake value based on observed or 
experimentally determined approximations or estimates of nutrient intake by a group (or 
groups) of healthy people that are assumed to be adequate – used when an RDA cannot be 
determined 
Tolerable Upper Intake Level (UL) is the highest level of nutrient intake that is likely to 
pose no risk of adverse health effects for almost all individuals in the general population.  
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Figure 3: Dietary reference intakes. 
NNR -Recommended Intake (NNR Project Group, 2012) 
Average Requirement (AR) is defined as the lowest long-term intake level of a nutrient 
that will maintain a defined level of nutritional status in an individual i.e. the level of a 
nutrient that is sufficient to cover the requirement for half of a defined group of individuals 
provided that there is a normal distribution of the requirement.  
ARNNR = EARIOM = AREFSA 
Recommended Intake (RI) is defined as the amount of a nutrient that meets the known 
requirement and maintains good nutritional status among practically all healthy individuals in 
a particular life stage or gender group. RI= AR + 2SDAR.  
RINNR = RDAIOM = PRIEFSA 
Upper Intake Level (UL) is defined as the maximum level of long-term (months or years) 
daily nutrient intake that is unlikely to pose a risk of adverse health effects in humans.  














Figure 4: Derivation of Upper Intake Level (UL)  
UF: Uncertainty factor 
Expert group on vitamins and minerals (EVM), UK (EVM, 2003) 
Safe Upper Intake Level (SUL): EVM used SUL instead of UL and defined SUL as the 
determination of doses of vitamins and minerals that potentially susceptible individuals could 
take daily on a life-long basis, without medical supervision in reasonable safety. The setting 
of these levels provided a framework within which the consumer could make an informed 
decision about intake, having confidence that harm should not ensue. The levels so set will 
therefore tend to be conservative. 
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Background as provided by the 
Norwegian Food Safety Authority 
Directive 2002/46/EC on food supplements was implemented in Norwegian law in 2004 in 
Regulation 20 May 2004 No. 755 on food supplements. Pursuant to Directive 2002/46/EC, 
common maximum and minimum levels of vitamins and minerals in food supplements shall 
be set in the EU. 
National maximum limits for vitamins and minerals were established in the former vitamin 
and mineral supplements regulation from 1986 and were continued in the 2004 regulation.  
The European Commission started establishing common limits in 2006, but the work was 
temporarily put on standstill in 2009. The time frame for the further work is not known.  
Maximum limits for levels of vitamins and minerals in food supplements shall be set on the 
basis of the following criteria, pursuant to article 5 in Directive 2002/46/EC:  
 Upper safe levels of vitamins and minerals established by scientific risk assessment 
based on generally accepted scientific data, taking into account, as appropriate, the 
varying degrees of sensitivity of different consumer groups  
 Intake of vitamins and minerals from other dietary sources 
When the maximum levels are set, due account should also be taken of reference intakes of 
vitamins and minerals for the population. 
Pending establishment of common maximums limits in the EU, the Norwegian Food Safety 
Authority is evaluating the national maximum limits for vitamins and minerals in food 
supplements. 
Assessment of niacin 
The Norwegian Food Safety Authority will evaluate the national maximum limits for niacin in 
the food supplement regulation. The minimum and maximum limits for the content of 
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Background Table: Minimum and maximum limits for niacin in the food supplement regulation 
(December 2016). 
 Minimum amount per 
recommended daily dose 
Maximum amount per 
recommended daily dose 
Niacin, mg niacin equivalents 4 32 
Permitted niacin substances which may be used in the manufacture of food supplements are 
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Terms of reference as provided by the 
Norwegian Food Safety Authority 
The Norwegian Food Safety Authority (NFSA, Mattilsynet) requests the Norwegian Scientific 
Committee for Food Safety (VKM) to assess the intake of niacin from the diet, including 
fortified products, in all age groups in the population above 1 year (mean intakes, median, 
P5, P95). Separate calculations are requested for nicotinamide and nicotinic acid. 
VKM is also requested to conduct scenario calculations to illustrate the consequences of 
establishing separate maximum limits for nicotinic acid (1, 4, 8 or 10 mg/day) and 
nicotinamide (100, 500, 700 or 900 mg/day) in food supplements, and to evaluate these 
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Assessment niacin, nicotinamide and 
nicotinic acid 
1 Introduction 
The term niacin comprises the two main water-soluble forms nicotinic acid (nicotinate, 3-
pyridinecarboxylic acid, pyridine-beta-carboxylic acid, and niacin; molecular weight 123) and 
nicotinamide (3-pyridinecarboxamide, nicotinic acid amide and niacinamide; molecular 
weight 122).  
In food, niacin is mainly present as bound forms that require hydrolysis to release the free 
nicotinic acid or nicotinamide prior to absorption. Nicotinic acid is mainly bound to 
macromolecules in plants, while nicotinamide is usually a component of nicotinamide adenine 
dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) in animal 
tissue. Niacin may also be synthesised from the essential amino acid, tryptophan. Despite a 
low efficiency of this process, tryptophan, obtained both from food and from tissue protein 
breakdown, is considered important to the overall niacin content in the body.  
Niacin-rich foods include liver, meat, and fish, mainly as NADH, NADPH (coenzymes in their 
reduced states), nicotinate, and nicotinamide. The outer (aleurone) layer of grains (but not 
the endospermium) is relatively niacin-rich, though much of this may be in the form of 
complexes with carbohydrates (niacytins) or peptides (niacinogens) (Kohlmeier, 2015). 
These niacin-containing macromolecules have low bioavailability (Carter and Carpenter, 
1982). Niacin can be released from niacytin complexes, such as maize (corn) and millet, by 
treatment with alkali (van den Berg, 1997).   
Dietary intake is expressed as milligram niacin equivalents (NEs), which correspond to 1 mg 
of pure niacin or 60 mg of tryptophan (the alternate precursor of NAD and NADP). The 
Nordic Nutrition Recommendations (NNR, 2012) has reported that the diet in the Nordic 
countries provides 33-43 NE/MJ. 
Nicotinic acid and nicotinamide are absorbed in the small intestine by carrier-mediated 
facilitated diffusion. Both are transported in the plasma in free solution, but nicotinamide is 
the major form of niacin present in blood (Kirkland, 2014). Further, nicotinic acid and 
nicotinamide are taken up by most tissues by passive diffusion, except some tissues (e.g. 
erythrocytes, kidney, brain) which require a carrier (Gropper et al., 2009; Henderson, 1983). 
Nicotinamide and nicotinic acid are retained in tissues by being converted mostly to NAD and 
NADP in their reduced states (NADH/NADPH). These coenzymes are the most central 
electron carriers of cells, playing essential roles as co-substrates of more than 200 enzymes 
involved in the metabolism of carbohydrates, fatty acids, and amino acids. The NAD-
dependent reactions are involved in intracellular respiration, whereas most of the NADP-
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dependent reactions serve biosynthetic (e.g., fatty acids, sterols) functions (Combs, 2000). 
McCreanor and Bender (1986) have shown that even extremely high intake of nicotinamide 
or nicotinate will not result in greatly increased NAD production, despite the capacity for 
promoting NAD synthesis via the trypthophan/quinolate pathway. Regulation mechanisms of 
NAD production, however, is not well understood.  
Long-term inadequate intake of niacin and tryptophan is associated with risk of developing 
pellagra. Symptoms of pellagra include fatigue, headache, apathy, depression, memory loss, 
dementia, pigmented skin rash after sun exposure, bright red tongue, vomiting, diarrhea, 
and constipation (Kohlmeier, 2015). 
Flushing (burning and itching of the face, arms, and chest) and stomach irritation are the 
main side effects of moderately high supplemental intake of nicotinic acid (more than 
35 mg/day). Long-term use of high doses (≥3000 mg/day) of nicotinic acid as cholesterol-
lowering drug, can also be to toxic to the liver (Kohlmeier, 2015). High intake of nicotinic 
acid may also interfere with the effects of sulfinpyrazone (Anturane) (Kohlmeier, 2015). 
Nicotinamide, however, does not have these adverse effects and nicotinamide toxicity in 
general appears to be quite low. 
There are no studies suggesting any adverse effects from consumption of nicotinamide and 
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2 Recommendations and tolerable 
upper intake levels 
2.1 Recommendations 
The primary method used to estimate the requirement for niacin relates intake to the urinary 
excretion of niacin metabolites. The requirement is expressed in niacin equivalents, allowing 
for some conversion of the amino acid tryptophan to niacin. 
The NNR of 2012 concluded that in absence of new scientific data, the recommended intake 
of niacin given in NNR 2004 remained unchanged. The Norwegian recommended intakes for 
niacin for the different age groups, based on NNR (2012), are presented in Table 2.1-1 
(Helsedirektoratet, 2014; NNR Project Group, 2012). 
Table 2.1-1 Recommended intakes (RI) for niacin in Norway, both sexes. 
Age, both sexes NE 
 Men Women 
1-2 years 7 7 
2-5 years 9 9 
6-9 years 12 12 
10-13 years 15 14 
14-17 years 19 16 
18-30 years 19 15 
31-60 years 18 14 
61-74 years 16 13 
>75 years 15 13 
Pregnant  17 
Lactating  20 
In 2014, the European Food Safety Authority (EFSA) concluded that no new scientific data 
have become available to change the Population Reference Intake (PRI) for niacin set by SCF 
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2.2 Tolerable upper intake levels 
Institute of Medicine (IOM, 1998), USA 
IOM (1998) stated that there was no evidence of adverse effects from the consumption of 
naturally occurring niacin in foods. Therefore, the identification of a tolerable upper intake 
level (UL) was limited to evidence concerning intake of niacin as a supplement, food 
fortificant, or pharmacological agent. 
IOM reported that flushing, nonspecific gastrointestinal effects, hepatotoxicity, glucose 
intolerance and ocular effects had been identified in previous studies after niacin treatment. 
Flushing that results in patients deciding to change the pattern of niacin intake (i.e., reduce 
the amount taken at a time or withdraw from treatment) was selected as the most 
appropriate endpoint on which to base a UL. The report from IOM described that flushing 
was the adverse effect first observed after excess niacin intake and has been generally 
observed at lower doses than other adverse effects. In addition, the report underlined that 
“although nicotinamide appears not to be associated with flushing effects, a UL for nicotinic 
acid that is based on flushing is considered protective against potential adverse effects of 
nicotinamide”. According to IOM, the data on hepatotoxicity was considered less relevant to 
the general population because they involved large doses taken for long periods of time for 
the treatment of a medical condition. 
The data sets that were used to identify the lowest-observed-adverse-effect level (LOAEL) 
for niacin included anecdotal reports and clinical trials involving oral intake of niacin by 
healthy individuals. Studies involving parenteral administration were not considered in the 
dose-response assessment. Furthermore, studies involving immediate-release forms of niacin 
were considered more relevant to niacin intake by the general population than were studies 
involving sustained-release forms. 
The IOM-report stated that the data were not adequate to identify a no-observed-adverse-
effect level (NOAEL) for flushing. On the other hand, flushing reactions which resulted in a 
patient either changing the form or amount of niacin used or withdrawing from treatment 
were considered relevant for identification of a LOAEL.  
IOM used a study by Sebrell and Butler (1938) to set a LOAEL of 50 mg nicotinic acid per 
day and deriving a UL because it provided the lowest effect level. In that study, four out of 
six persons experienced a flushing sensation after oral intake of 50 mg/day of nicotinic acid 
given with meals for 92 days. In one of the four subjects who experienced flushing effects, 
the daily dose of 50 mg was given as 25 mg in the morning and evening. Although this study 
also reported a flushing reaction in one of six subjects taking 30 mg of nicotinic acid daily on 
day 32 of intake, this reaction was not bothersome enough to change the dosing pattern.  
In addition, IOM described that a study by Spies et al. (1938) provided supportive evidence 
for a LOAEL of 50 mg/day. In this study, five of 100 individuals (5%) experienced flushing 
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after a single oral dose of 50 mg of nicotinic acid, 50 individuals (50%) experienced flushing 
after 100 mg, and all individuals experienced flushing after 500 mg. 
A case report was also mentioned, which showed that 14 of 69 persons (20%) experienced 
onset of rash, itching, and a sensation of warmth about 30 minutes after consuming one or 
more pumpernickel bagels to which niacin had been inadvertently added from an improperly 
labelled container (CDC, 1983 cited in IOM, 1998). The bagels were found to contain an 
average of 190 mg of nicotinic acid. 
Due to the transient nature of the flushing effect, a small uncertainty factor (UF) of 1.5 was 
selected. IOM stated that a smaller UF was not appropriate because it is applied to a LOAEL 
rather than a NOAEL. 
Thus, a LOAEL of 50 mg/day was divided by a UF of 1.5 to obtain the UL for adults of 
35 mg/day, a rounded estimate. 
The IOM report did not identify any data suggesting that other life stage groups have 
increased susceptibility to flushing effects from excess niacin intake. Therefore, the UL of 
35 mg/day was also considered to apply for pregnant and lactating adult women. For 
children aged 1 year and older and adolescents up to age 18 years, the UL identified for 
adults (of 35 mg/day) was adjusted on the basis of relative body weights. The UL was 
judged not determinable for infants because of a lack of data on adverse effects in this age 
group and concern about the infant’s ability to handle excess amounts. In order to prevent a 
high intake of niacin, IOM (1998) recommended that the only source of intake for infants 
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Table 2.2-1 Tolerable upper intake levels for niacin in different age groups adjusted by body 
weight suggested by the IOM (1998).  









Scientific Committee for Food (SCF, 2002), EU 
According to SCF (2002), the only reports of adverse effects associated with the ingestion of 
niacin with food have occurred following the addition of free nicotinic acid to food prior to 
consumption. Thus, the report from SCF (2002) has underlined that all of the available data 
on hazard identification and characterisation relate to studies following the administration of 
either nicotinic acid or nicotinamide. The SCF developed separate ULs for nicotinic acid and 
nicotinamide due to the difference in adverse effect profiles. 
Nicotinic acid 
According to SCF, the adverse effects associated with excessive intakes of nicotinic acid 
included flushing, gastrointestinal effects such as dyspepsia, diarrhoea and constipation, 
hepatotoxicity, glucose intolerance in addition to some other rare effects (e.g. blurred vision, 
macular oedema and increased plasma homocysteine concentrations). Further, SCF has 
described that the limiting adverse effect at lower doses is flushing, whereas the most severe 
and potentially life-threatening adverse effects, such as hepatotoxicity, occur principally at 
much higher doses of nicotinic acid (higher than 500 mg/day). Although flushing might be 
considered a minor health effect, it was used as the basis for setting the UL for nicotinic acid 
due to concerns about the risk of transient hypotensive episodes, especially in the elderly. 
In line with IOM (1998), the report from SCF refers to the studies conducted by Sebrell and 
Butler (1938) and Spies et al. (1938) for derivation of a tolerable upper intake level of 
nicotinic acid.  As previously mentioned, Spies et al. (1938) reported only 5% incidence of 
flushing after a single oral dose of 50 mg nicotinic acid and a 50% incidence at 100 mg. The 
uncontrolled study by Sebrell and Butler (1938), in which groups of six subjects were given 
10, 30 or 50 mg nicotinic acid daily for 92 days, reported flushing intermittently in 0, 2 and 4 
individuals, respectively. 
Although SCF (2002) underlined that flushing would be unlikely to occur repeatedly in 
subjects given less than 50 mg/day, the study by Sebrell and Butler (1938) which showed 
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occasional flushing at 30 mg nicotinic acid per day (LOAEL) was used to establish a UL. An 
uncertainty factor of 3 was used to allow for the fact that a slight effect was reported, and 
that the study was performed in a small number of subjects, but taken into account the 
steep dose-response relationship. Thus, the UL for nicotinic acid was established at 10 
mg/day. 
According to SCF, this UL is 300-fold below the dose frequently used clinically for the 
treatment of hypercholesterolaemia (3 g/day) and which is associated with a high incidence 
of serious adverse reactions. 
Finally, SCF (2002) states that the UL of 10 mg/day for free nicotinic acid is not applicable 
during pregnancy or lactation because of inadequate data relating to this critical life stage. 
The upper levels for intake by children and adolescents was derived on the basis of their 
body weights. 
Table 2.2-2 Tolerable upper intake levels for nicotinic acid in different age groups adjusted for 
body weight suggested by the SCF (2002). 







* Not applicable during pregnancy and lactation. 
Nicotinamide 
The report from SCF (2002) stated that nicotinamide does not produce the flushing response 
that has been used as the basis for the UL for nicotinic acid and that gastrointestinal effects 
following high-dose treatment with nicotinamide are rare. Only one reported case of 
hepatotoxicity in a patient receiving high-dose nicotinamide was identified. SCF underlined, 
however, that no significant adverse effects have been reported in trials investigating 
possible benefits of nicotinamide in patients with or at risk of diabetes, which have used 
doses up to the equivalent of 3 g per day, for periods up to 3 years (Mendola et al, 1989; 
Chase et al, 1990; Vague et al, 1987; IMDIAB III trial; DENIS trial all cited in SCF, 2002).  
Based on these latter mentioned studies, a NOAEL for nicotinamide was set to 25 mg/kg 
bw/day. SCF argued that this value represented the lowest reported dose in a number of 
trials of high quality, many of which used sensitive markers of hepatic function and glucose 
homeostasis, and included a range of age groups, with some subjects treated with up to 
50 mg/kg bw/day.  
An uncertainty factor of 2 was used to allow for the fact that adults may eliminate 
nicotinamide more slowly than the study groups, many of which were children, and that data 
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for children would not reflect the full extent of inter-subject variability that could occur in an 
older population.  
Thus, the UL for nicotinamide was established at 12.5 mg/kg bw/day or approximately 900 
mg/day for adults. 
According to the SCF report, the UL of 900 mg/day for nicotinamide is not applicable during 
pregnancy or lactation because of inadequate data relating to this critical life stage. The ULs 
for children and adolescents were derived on the basis of their body weights. 
Table 2.2-3 Tolerable upper intake levels for nicotinamide in different age groups adjusted for 
body weights suggested by the SCF (2002). 







* Not applicable during pregnancy and lactation. 
Expert Group on Vitamins and Minerals (EVM, 2003), UK 
Although the report from EVM (2003) concluded that there were insufficient data from 
human or animal studies to establish a Safe Upper Level, the report present guidance levels 
for nicotinic acid and nicotinamide, respectively.  
Nicotinic acid 
In line with IOM and SCF, EVM has also acknowledged adverse effects from the use of large 
doses of nicotinic acid in the treatment of hypercholesterolemia, including flushing, skin 
itching, nausea, vomiting and gastrointestinal disturbance. At higher intakes of nicotinic acid 
over long period of time, liver dysfunction has been reported. According to EVM, other 
adverse effects which has been identified includes hyperglycaemia and adverse 
ophthalmological effects such as blurred vision and cystoid macular oedema. 
For risk assessment of nicotinic acid, EVM has, in line with the previously mentioned reports, 
referred to the studies conducted by Spies et al. (1938) and Sebrell and Butler (1938). In 
addition, EVM has referred to case reports and controlled clinical trials, in which doses of 
approximately 3000 mg/day nicotinic acid have apparently caused hepatotoxic effects (the 
Coronary Drug Project, 1975; Knopp et al., 1985; Fraunfelder et al., 1995, all cited in EVM, 
2003). The randomised double-blind Coronary Drug Project was especially emphasised, in 
which one third or more of 1119 patients who received 3000 mg nicotinic acid/day for up to 
5 years were reported to have elevated levels of liver enzymes. Elevations in serum uric acid 
levels and an increased incidence of gout were also reported. 
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In line with other reports, the two studies by Spies et al. (1938) and Sebrell and Butler 
(1938), were used as the basis for setting the upper level for nicotinic acid. Thus, 50 mg 
nicotinic acid per day was set as a LOAEL and an uncertainty factor of 3 was applied to 
extrapolate to a NOAEL, which resulted in a guidance level for supplementation only of 
17 mg/day (50/3). EVM emphasised that this guidance level was given for supplements only, 
as free nicotinic acid levels in food are low and adverse effects appear to be related to acute, 
bolus intakes of nicotinic acid, rather than more sustained exposure as would occur with 
ingestion of nicotinic acid via food.  
EVM has also emphasised that their guidance level was based on intakes of conventional 
formulations of nicotinic acid and, therefore, would not be applicable to sustained release 
preparations which is thought to be more hepatoxic. Nicotinic acid contained in food 
supplements, however, is not in the sustained release form. 
Nicotinamide 
In line with other reports, EVM (2003) emphasised that few data were available on the 
safety of nicotinamide, but the occurrence of nicotinamide toxicity appeared to be quite low. 
According to EVM, studies have shown that doses up to 3000 mg/day for periods up to 3 
years seem to be well tolerated, but most of these trials have studied only one dose level 
and included only a small number of participants (Vague et al., 1987; Mendola et al., 1989; 
Chase et al., 1990; Pozzilli et al., 1995; Lampeter et al., 1998 all cited in EVM, 2003). Two of 
these studies were used as a basis for establishing guidance level of nicotinamide; a study 
conducted by Pozzilli et al. (1995) and Lampeter et al. (1998). Results from these studies 
showed that doses of 25 and 42 mg/kg bw/day did not affect biochemical parameters such 
as liver and kidney function tests in small groups of Type 1 diabetics (or those at high risk of 
developing the condition). 
Due to methodological limitations of these studies and to account for inter-individual 
variability because of the nature of the study population, EVM used an uncertainty factor of 
3. 
Thus, a guidance value, for supplementation of nicotinamide only, was established at 
8.3 mg/kg bw/day (25/3), or approximately 500 mg supplemental nicotinamide per day for 
60 kg adults.  
Due to lack of data on the safety of nicotinamide in pregnancy, EVM has emphasised that 
these guidance values do not apply to pregnant women.  
Nordic Nutrition Recommendations (NNR, 2012) 
NNR (2012) has described that there were no studies indicating adverse effects of 
consumption of naturally occurring niacin in foods. In line with other reports, NNR emphasize 
that intakes of nicotinic acid, but not nicotinamide, as a supplement or fortificant in the 
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range of 30 mg/day to 1000 mg/day can result in mild symptoms such as flushing. Higher 
intakes have been reported to induce liver damage.  
NNR (2012) supported the ULs set by SCF in 2002. 
 Summary of tolerable upper intake levels 
Table 2.2.1-1 summarises available tolerable upper intake levels or guidance levels for 
nicotinic acid and nicotinamide in adults. 
Table 2.2.1-1 Overview of ULs or guidance levels in adults set by various authorities.  
*Guidance levels, not sufficient data to establish SUL 
Intake of niacin (either as nicotinic acid or as nicotinamide) from food sources has not been 
reported to cause adverse effects. The hazard identification revealed flushing as the most 
sensitive adverse health effect of nicotinic acid from supplements. Furthermore, 
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glucose intolerance in addition to some other rare effects (e.g. blurred vision, macular 
oedema and increased plasma homocysteine concentrations) has been reported. 
Nicotinamide, however, does not have these effects. In general, nicotinamide toxicity seems 
to be quite low; only one reported case of hepatotoxicity in a patient receiving high-dose 
nicotinamide was identified and no significant adverse effects were reported in trials on the 
possible benefits of nicotinamide in patients with or at risk of diabetes, which have used 
doses up to the equivalent of 3 g per day, for periods up to 3 years (Mendola et al, 1989; 
Chase et al, 1990; Vague et al, 1987; IMDIAB III trial; DENIS trial all cited in EVM, 2003).  
VKM proposes to adopt the tolerable upper intake levels of nicotinic acid and nicotinamide 
set by the SCF in 2002, which are based on one human dose-response study (nicotinic acid) 
and several human dose-response studies (nicotinamide), respectively. Hence, the UL for 
supplemental nicotinic acid is suggested to 10 mg/day for adults and the UL for 
supplemental nicotinamide to 900 mg/day for adults. The ULs for intake by children and 
adolescents have been derived on the basis of their body weights.  
Although SCF (2002), IOM (1998) and EVM (2003) have used the same dose-response study 
(Sebrell and Butler, 1938) as the main basis for setting the UL for supplemental nicotinic 
acid, they have not reached the same conclusions. In line with SCF, VKM has acknowledged 
that 2 out of 6 individuals reported flushing symptoms at daily doses of 30 mg nicotinic acid 
for 92 days in the study by Sebrell and Butler (1938), and that this is considered a LOAEL. 
Although flushing has been considered a minor health effect, it was used as the basis for 
setting the UL for nicotinic acid due to concerns about possible transient hypotensive 
episodes, especially in the elderly. VKM also support the use of an uncertainty factor of 3 
due to the limited number of studies which have included only a small number of 
participants. IOM (1998) did not establish separate UL for nicotinamide. EVM (2003) and SCF 
(2002) have based their upper levels for nicotinamide on the same NOAEL, but SCF applied a 
lower uncertainty factor (2) than EVM (3). VKM supports the UL for nicotinamide from SCF 
(2002) as in general, the risk of nicotinamide toxicity appears to be quite low. 
The tolerable upper intake levels set for nicotinic acid and nicotinamide concern only intake 
from supplements and fortification. There are no studies suggesting any adverse effects from 
consumption of nicotinamide and nicotinic acid naturally occurring in foods. 
Therefore, VKM has not conducted or evaluated scenarios with intake from both diet and the 
separated new maximum limits for nicotinic acid and nicotinamide in food supplements 
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3 Assessment of dietary intakes of 
niacin 
3.1 Short description of the Norwegian dietary surveys 
The estimated intakes of niacin presented in this opinion are based on data from the national 
food consumption surveys in young children (2-year-olds), children and adolescents (9- and 
13-year-olds) and adults (aged 18 to 70 years). The national food consumption surveys were 
conducted by the Department of Nutrition, University of Oslo in collaboration with the 
Directorate of Health and the Norwegian Food Safety Authority. Different methodologies 
were used in the tree different surveys and thus direct comparisons between the age groups 
may be misleading.  
A description of the food consumption surveys and the different methodologies used is given 
below.  
Adults: “Norkost 3” is based on two 24-hour recalls by telephone at least one month apart. 
Food amounts were presented in household measures or estimated from photographs 
(Totland et al., 2012). The study was conducted in 2010/2011, and 1787 adults (925 women 
and 862 men) aged 18-70 participated. 
9- and 13-year-old children/adolescents: “Ungkost 2003” is based on a 4-day food intake 
registration with a webbased food diary. All food items in the diary were linked to 
photographs for portion estimation (Hansen et al., 2016). The study was conducted in 2015 
and 636 9-year-old children and 687 13-year-old adolescents participated. 
4-year-old children: “Ungkost 2003” is based on a 4-day food intake registration with a 
webbased food diary. All food items in the diary were linked to photographs for portion 
estimation (Hansen et al., 2017). The study was conducted in 2016 and 399 4-year-olds 
participated. 
2-year-old children: “Småbarnskost 2007” is based on a semi-quantitative food frequency 
questionnaire. In addition to predefined household units, food amounts were also estimated 
from photographs. The study was conducted in 2007, and a total of 1674 2-year-olds 
participated (Kristiansen et al., 2009). 
3.2 Dietary intakes of niacin in the Norwegian population 
Intake of niacin in the various age groups and in groups of users of niacin supplements are 
presented in tables in Appendix 1. Separate values for nicotinic acid and nicotinamide is not 
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available in the Norwegian Food Database. The tables in Appendix 1 also include estimates 
for P25 and P75.  
Adults  
The mean intake of niacin from the diet alone is 22.2 mg/day (median 20.5 mg/day) in 
adults (n=1787). The P5 intake is 9.3 mg/day and the P95 intake is 41.4 mg/day. 
In Norkost 3, 394 participants (22%) reported use of niacin-containing supplements. Their 
mean total intake of niacin including that from food supplements is 34.3 mg/day (median 
30.8 mg/day), P5 intake is 17.7 mg/day and P95 intake is 60.1 mg/day. 
Mean intake of niacin from supplements alone in adults reporting use of niacin-containing 
supplements is 13.5 mg/day (median 9.0 mg/day), P5 intake is 4.0 mg/day and P95 intake is 
32.8 mg/day. 
In 13-year-olds (n=687) 
The mean intake of niacin from the diet alone is 15.3 mg/day (median 14.2 mg/day) in 13-
year-olds. The P5 intake is 7.2 mg/day and the P95 intake is 27.6 mg/day. 
In Ungkost 3, 156 13-year-olds (23%) reported use of niacin-containing supplements. Their 
mean total intake of niacin including that from food supplements is 26.0 mg/day (median 
25.0 mg/day), P5 intake is 12.8 mg/day and P95 intake is 41.2 mg/day. 
Mean intake of niacin from supplements alone in 13-year-olds reporting use of niacin-
containing supplements is 16.4 mg/day (median 15.8 mg/day), P5 intake is 7.4 mg/day and 
P95 intake is 30.9 mg/day. 
In 9-year-olds (n=636) 
The mean intake of niacin from the diet alone is 12.9 mg/day (median 11.9 mg/day) in 9-
year-olds. The P5 intake is 6.6 mg/day and the P95 intake is 22.3 mg/day. 
In Ungkost 3, 209 9-year-olds (33%) reported use of niacin-containing supplements. Their 
mean total intake of niacin including that from food supplements is 19.5 mg/day (median 
19.3 mg/day), P5 intake is 11.5 mg/day and P95 intake is 28.1 mg/day. 
Mean intake of niacin from supplements alone in 9-year-olds reporting use of niacin-
containing supplements is 7.1 mg/day (median 6.0 mg/day), P5 intake is 2.0 mg/day and 
P95 intake is 12.0 mg/day. 
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In 4-year-olds (n=399) 
The mean intake of niacin from the diet alone is 9.8 mg/day (median 9.4 mg/day) in 4-year-
olds. The P5 intake is 5.3 mg/day and the P95 intake is 15.0 mg/day. 
In Ungkost 3, 166 4-year-olds (39%) reported use of niacin-containing supplements. Their 
mean total intake of niacin including that from food supplements is 16.7 mg/day (median 
16.4 mg/day), P5 intake is 10.2 mg/day and P95 intake is 25.1 mg/day. 
Mean intake of niacin from supplements alone in 4-year-olds reporting use of niacin-
containing supplements is 9.5 mg/day (median 9.1 mg/day), P5 intake is 4.8 mg/day and 
P95 intake is 14.9 mg/day. 
In 2-year-olds (n=1674) 
The mean intake of niacin from the diet alone is 9.1 mg/day (median 8.7 mg/day) in 2-year-
olds. The P5 intake is 4.9 mg/day and the P95 intake is 14.8 mg/day. 
In Småbarnskost 2007, 554 2-year-olds (33%) reported use of niacin-containing 
supplements. Their mean total intake of niacin including that from food supplements is 21.4 
mg/day (median 20.6 mg/day). The P5 intake is 5 mg/day and the P95 intake is 24 mg/day. 
Mean intake of niacin from supplements alone in 2-year-olds reporting use of niacin-
containing supplements is 9.0 mg/day (median 8.6 mg/day). P5 intake is 4.9 mg/day and 
P95 intake is 14.7 mg/day. 
3.3 Assessment of the intakes of niacin 
Intake of niacin from foods has only been evaluated in relation to recommended intakes as 
the ULs only apply for food supplements and fortification agents. Dietary calculations for 
niacin have been performed for intake in P5, P25, mean, P50, P75 and P95 in children (2- 
and 9-year-olds), adolescents (13-year-olds) and in adults. Niacin intake from fortified 
products is not included in the calculations, but are however, evaluated to be low. 
Mean and median intakes of niacin from the diet alone (which includes both nicotinic acid 
and nicotinamide) are above or at the recommended intakes for all age groups.  
As described earlier, present maximum limits in food supplements is given for niacin only, 
and includes nicotinic acid, nicotinamide and inositol hexanicotinate. If we assume that all 
niacin in food supplements is present as nicotinic acid, all age groups have intakes from 
supplements alone above the ULs (mean, median and P95). Even in P5 the intakes in 2- and 
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4 Uncertainties 
It should be noted that the intakes have been calculated based on various dietary surveys 
for the different age categories and a comparison of calculations across age groups can be 
misleading. The calculated intakes in the higher and lower percentiles are always associated 
with a higher degree of uncertainty than mean or median intakes.  
Thus, the percentile estimates of dietary intake are prone to random error due to the limited 
number of participants in the dietary surveys. The degree of uncertainty is largest in the 
estimated percentiles for 4-year-olds with a sample size of n=399, corresponding to about 
20 observations below the 5-percentile and above the 95-percentile, respectively. 
Another issue is that low participation limits the representativeness of the participants 
compared with the general background population in Norway. The participation among 13-, 
9- and 4-year-olds in the dietary surveys were 53%, 55% and only 20%, respectively, while 
they were 37% in adults and 56% in 2-year-olds. In general, participants had considerably 
higher education level than the background population, and are expected to represent a 
health-conscious subgroup of the population. Some population subgroups are not covered, 
e.g. ethnic minorities.  
For the determinations of the ULs for nicotinic acid and nicotinamide, IOM, SCF and EVM 
have not reached the same conclusions, indicating uncertainty regarding establishment of 
these ULs both for adults, and even more for children and adolescents.  
The terms of reference have been to assess the intake in Norway in relation to already 
established tolerable upper intake levels which were established between 2000 and 2012. No 
literature search has been conducted for this VKM assessment and relevant recent evidence 
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5 Answers to the terms of reference 
The Norwegian Scientific Committee for Food Safety (VKM) has, at the request of the 
Norwegian Food Safety Authority (Mattilsynet; NFSA), assessed the intake of niacin from the 
diet, in all age groups in the population above 1 year in relation to tolerable upper intake 
levels (ULs).  
VKM was also requested to conduct scenario calculations to illustrate the consequences of 
establishing separate maximum limits for nicotinic acid (1, 4, 8 or 10 mg/day) and 
nicotinamide (100, 500, 700 or 900 mg/day) in food supplements, and to evaluate these 
scenarios against existing tolerable upper intake levels (ULs). The previous maximum limit 
for niacin was 32 mg/day, including nicotinic acid, nicotinamide and inositol hexanicotinate. 
Dietary calculations have been performed for niacin intake in the P5, P25, mean, P50, P75 
and P95 in children (2- and 9-year-olds), adolescents (13-year-olds) and among adults. 
Mean and median intakes of niacin from diet alone are above or at the recommended intakes 
for all age groups.  
The ULs set for the two main forms of niacin; nicotinic acid and nicotinamide concern only 
intakes from supplements, since intake of niacin from regular foods is considered to be 
without risk of negative health effects. Therefore, VKM has not conducted or evaluated 
scenarios with intake from both diet and the separated new maximum limits for nicotinic acid 
and nicotinamide in food supplements suggested by NFSA. As a result, the tolerable upper 
intake levels for nicotinic acid and nicotinamide for the various age groups equals the 
amounts that can be tolerated in food supplements and in fortified products. Niacin intake 
from fortified products is not included in the calculations, but are however, evaluated to be 
low. 
VKM proposes to adopt the UL for supplemental nicotinic acid and nicotinamide set by the 
Scientific Committee for Food Safety (SCF) in 2002, which are suggested to 10 mg/day and 
900 mg/day, respectively, for adults. The ULs for intake by children and adolescents have 
been derived on the basis of their body weights.  
Because tolerable upper intake level for supplemental nicotinic acid is 10 mg/day for adults, 
none of the suggested maximum limits in food supplements (1, 4, 8, or 10 mg/day) will lead 
to exceedance of this tolerable upper intake level in adults. In 13-year-olds and 9-year-olds, 
supplements with 8 mg nicotinic acid per day, and in 4-year-olds and 2-year-olds, 
supplementation of 4 mg nicotinic acid per day will lead to exceedance of the tolerable upper 
intake level of nicotinic acid. An overview of the conclusions is presented in Table 5-1. 
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Adults     
13 years     
9 years      
4 years     
2 years      
Green: No exceedance of the UL 
Red: Exceedance of the UL 
Further, because tolerable upper intake level for supplemental nicotinamide is 900 mg/day 
for adults, none of the suggested maximum limits in food supplements (100, 500, 700 or 900 
mg/day) will lead to exceedance of this tolerable upper intake level in adults. In 13-year-
olds, supplements with 700 mg nicotinamide per day, and in and 9-year-olds, 4-year-olds 
and 2-year-olds, supplementation of 500 mg nicotinamide per day will lead to exceedance of 
the tolerable upper intake level of nicotinic acid. An overview of the conclusions is presented 
in Table 5-2. 
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6 Data gaps 
There is a lack of long-term well-designed studies with a high number of participants that 
specifically examine possible adverse health effects of nicotinic acid and nicotinamide, 
respectively. 
More age groups should be included in dietary surveys in addition to subgroups like different 
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Appendix I 
Summary tables of niacin intake for all age groups 
Intakes of niacin in the various age groups are presented in the tables below. The tables 
summarise intakes from the diet alone, niacin-containing supplements alone (users only) and 
total intakes from both diet and supplements (Tables 1 and 2).  











Niacin from diet alone, mean 22.2 15.3 12.9 9.8 9.1 
Niacin from diet alone, median 20.5 14.2 11.9 9.4 8.7 
Niacin from diet alone, P5 9.3 7.2 6.6 5.3 4.9 
Niacin from diet alone, P25 15.0 10.4 9.6 7.6 7.0 
Niacin from diet alone, P75 26.7 18.6 15.1 11.6 10.8 
Niacin from diet alone, P95 41.4 27.6 22.3 15.0 14.8 
Table 2 Niacin supplement users intake of total niacin from diet and supplements, and from 
supplements alone (users only), in various age groups (mg/day). 
 Adults  
(n=394) 
13 years  
(n=156) 
9 years  
(n=209) 
4 years  
(n=166) 
2 years  
(n=554) 
Total niacin from diet and supplements, 
mean 
34.3 26.0 19.5 16.7 14.8 
Total niacin from diet and supplements, 
median 
30.9 25.0 19.3 16.4 14.3 
Total niacin from diet and supplements, 
P5 
17.7 12.8 11.5 10.2 7.7 
Total niacin from diet and supplements, 
P25 
24.2 20.4 16.0 13.7 11.3 
Total niacin from diet and supplements, 
P75 
39.5 31.0 22.9 19.3 17.9 
Total niacin rom diet and supplements, 
P95 
60.1 41.2 28.1 25.1 23.8 
Niacin from supplements alone, mean 22.8 9.6 12.3 7.2 9.0 
Niacin from supplements alone, median 19.8 9.0 11.5 8.0 8.6 
Niacin from supplements alone, P5 9.1 3.0 6.6 2.0 4.9 
Niacin from supplements alone, P25 15.1 4.0 9.4 5.0 6.8 
Niacin from supplements alone, P75 24.7 12.0 14.5 9.0 10.8 
Niacin from supplements alone, P95 36.8 17.5 21.7 12.0 14.7 
 
